PR Newswire press releases
Full-text press releases distributed by PR Newswire, newest first. Times are US Eastern.
Source: PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lennar Corporation - LEN
Pomerantz LLP is investigating claims on behalf of investors of Lennar Corporation ("Lennar" or the "Company") (NYSE: LEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Six Flags Entertainment Corporation- FUN
Pomerantz LLP is investigating claims on behalf of investors of Six Flags Entertainment Corporation ("Six Flags" or the "Company") (NYSE: FUN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Concentrix Corporation - CNXC
Pomerantz LLP is investigating claims on behalf of investors of Concentrix Corporation ("Concentrix" or the "Company") (NASDAQ: CNXC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FMC Corporation - FMC
Pomerantz LLP is investigating claims on behalf of investors of FMC Corporation ("FMC" or the "Company") (NYSE: FMC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enova International, Inc. - ENVA
Pomerantz LLP is investigating claims on behalf of investors of Enova International, Inc. ("Enova" or the "Company") (NYSE: ENVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silvercorp Metals Inc. - SVM
Pomerantz LLP is investigating claims on behalf of investors of Silvercorp Metals Inc. ("Silvercorp" or the "Company") (NYSE: SVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mueller Industries, Inc. - MLI
Pomerantz LLP is investigating claims on behalf of investors of Mueller Industries, Inc. ("Mueller" or the "Company") (NYSE: MLI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Greenland Energy Company - GLND
Pomerantz LLP is investigating claims on behalf of investors of Greenland Energy Company ("Greenland Energy" or the "Company") (NASDAQ: GLND). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FreightCar America, Inc. - RAIL
Pomerantz LLP is investigating claims on behalf of investors of FreightCar America, Inc. ("FreightCar" or the "Company") (NASDAQ: RAIL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Primoris Services Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Primoris Services (PRIM)
Primoris Services Corporation (PRIM) shareholders have watched the Company's 2026 adjusted earnings-per-share outlook shrink from $4.80 to $5.00 down to $2.05 to $2.60 since June 22, 2026, and the third-quarter 2026 report has now cut full-year guidance again. If you bought PRIM and lost money, the earnings outlook behind your shares has been cut twice since June. Investors who suffered losses are encouraged to submit their PRIM loss details now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Veracyte (NASDAQ: VCYT) shareholders are taking losses after the Company's November 4, 2026 third-quarter report showed Decipher Prostate test volume short of management's own expectations. If you held VCYT through the decline, you may have legal rights. Investors who lost money are encouraged to report their VCYT losses here . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Gibraltar Industries Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Gibraltar Industries (ROCK)
Gibraltar Industries (NASDAQ: ROCK) shares fell more than 25% by market open on November 5, 2026, as the Company's third-quarter Form 10-Q filed with the Securities and Exchange Commission reported $1.2 billion of net debt, a 55% decline in Agtech backlog, and reduced full-year 2026 guidance. If you bought ROCK before this filing and are holding losses, you may have legal rights. You are encouraged to start your ROCK loss review here today. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the first patient has been dosed in China in the Phase I ATTRACT study evaluating ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE) in adult patients with B cell-mediated autoimmune diseases.
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the first patient has been dosed in China in the Phase I ATTRACT study evaluating ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE) in adult patients with B cell-mediated autoimmune diseases.
NEXT IS NOW: CFMOTO Brings Its Global Vision to Life at EICMA 2026
Under the theme "NEXT IS NOW," CFMOTO showcased its latest products and progress toward becoming a premium global powersports brand at EICMA 2026, with two press conferences.
CIEE to Strengthen Ties Between the United States and the Baltic States
The Council on International Educational Exchange (CIEE) today announced new U.S.-Baltic exchange programs that will expand opportunities for young Americans and students from the Baltic countries – Estonia, Latvia, and Lithuania – to develop critical career skills, international networks, and life-time connections in one another's countries.
Greenberg Traurig Expands Stadium Financing & Development Team, Adding Real Estate Attorney Jason Goldstein in New York
Global law firm Greenberg Traurig, LLP has further strengthened its capabilities in stadium and arena financing and development with the addition of real estate attorney Jason Goldstein as a shareholder in its New York office.
CCB Investors Have Opportunity to Lead Coastal Financial Corporation Securities Fraud Lawsuit
CCB Investors Have Opportunity to Lead Coastal Financial Corporation Securities Fraud Lawsuit
The Next Frontier: Consciousness & UAP: $100,000 Research Prize Winner Announced
The winning study, selected from more than 80 qualifying proposals, comes from a multidisciplinary team of six. Peter Skafish, PhD, a sociocultural anthropologist and Co-Founder and Executive Director of The Sol Foundation, leads the team as Principal Investigator. Brian Lord, PhD, a cognitive neuroscientist and postdoctoral researcher at the University of Arizona, serves as Co-Principal Investigator, and David Dominguez Hooper, engineer and Founder and CEO of ELDAEON Inc., is Co-Investigator. Collaborators are Damon Abraham, PhD (experimental psychologist, Entangled Labs); Jacob Haqq-Misra, PhD (astrobiologist, Blue Marble Space); and Garry Nolan, PhD (immunologist, Stanford University School of Medicine). For the first time in the prize's four-year history, a single team will receive the full $100,000.
DNB Final: DNB Investors Have Opportunity to Lead Dun & Bradstreet Holdings, Inc. Securities Fraud Lawsuit Filed
DNB Final: DNB Investors Have Opportunity to Lead Dun & Bradstreet Holdings, Inc. Securities Fraud Lawsuit Filed
AusperBio Reports Sustained Functional Cure up to 15 Months Off All HBV Treatment in Treatment-Naïve and NA-Treated Patients with Chronic Hepatitis B
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together, "AusperBio"), a biopharmaceutical company developing oligonucleotide therapeutics, today announced long-term follow-up data from Study AB-10-8004 evaluating the durability of functional cure achieved with AHB-137, its investigational antisense oligonucleotide (ASO) therapy for chronic hepatitis B (CHB). The findings show that functional cure can be maintained for up to 15 months after stopping all HBV treatment in both NA-treated and treatment-naïve participants. The data will be presented in two late-breaking oral presentations at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5–9 in Denver, Colorado.
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) and follow-up results from its Phase 2b ENRICH and ENHANCE studies in three late-breaking presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Denver, Colorado, from November 5 to 9, 2026.
Creating Homes Without Barriers: Andersen's Longstanding Work with Jared Allen's Homes for Wounded Warriors
A home should be a place of comfort, safety and independence. For veterans who have sustained life-changing injuries while serving our country, a home designed around their unique needs can make a meaningful difference in everyday life, helping create greater accessibility, mobility and confidence at home.
Malaysia-China (Chengdu) Collaboration Opens New Doors for Local Businesses and Talent
Malaysian businesses and innovation organisations explored opportunities to strengthen their technology capabilities and develop new partnerships at a Malaysia–China (Chengdu) technology matchmaking event held in Kuala Lumpur, organised by Intrinsic SEA Sdn Bhd as part of the organising team.
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) and follow-up results from its Phase 2b ENRICH and ENHANCE studies in three late-breaking presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Denver, Colorado, from November 5 to 9, 2026.
3D Systems Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into 3D Systems (DDD)
A positive $3.1 million adjusted EBITDA figure and a $33.5 million GAAP net loss appeared in the same 3D Systems Corporation (NYSE: DDD) third-quarter report on November 4, 2026. The Company also reported a widening year-over-year net loss and issued fourth-quarter revenue guidance of $100 million to $103 million. If you bought DDD shares and lost money, you may be entitled to seek a recovery. Shareholders holding DDD losses are encouraged to submit their loss details now. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Signature Aviation and JA Worldwide Team Up to Inspire the Next Generation of Aviation Professionals
Signature Aviation, the world's largest network of private aviation terminals, and JA (Junior Achievement) Worldwide are bringing aviation career opportunities to life for students through a new partnership focused on workforce readiness and career exploration.
TIGR Investors Have Opportunity to Lead UP Fintech Holding Limited Securities Fraud Lawsuit Filed by The Rosen Law Firm
TIGR Investors Have Opportunity to Lead UP Fintech Holding Limited Securities Fraud Lawsuit Filed by The Rosen Law Firm
Harrison Street and Aegis Living announce strategic joint venture partnership to expand access to high-quality senior living communities
Aegis Living (the family-operated assisted living and memory care company founded in 1997) and Harrison Street Asset Management ("Harrison Street"), a leading alternative global investment management firm with over $110 billion in assets under management through highly differentiated assets across infrastructure, real estate, and credit strategies, today announced a strategic joint venture partnership focused on investing in and developing high-quality assisted living and memory care communities. The partnership brings together Aegis Living's longstanding reputation for exceptional resident care and operations with Harrison Street's extensive senior housing investment experience and network of leading operating partners.
Baltimore Ravens and MedStar Health Treat Cancer Patients to Ultimate Tailgate Experience
The unmistakable sounds of the Ravens Marching Band traveled throughout the parking lots and hospital lobby, beckoning all in earshot to join the football fun. This year marked the second annual Ravens Crucial Catch Tailgate Experience for cancer patients and their families.
Honeywell Aerospace Deadline: HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit
Honeywell Aerospace Deadline: HONA Investors Have Opportunity to Lead Honeywell Aerospace Inc. Securities Fraud Lawsuit
Drake Software Expands Native AI Features for Tax Year 2026
This upcoming season, Drake Software®, a leader in professional tax preparation software, is putting more native AI capabilities to work right in the software that more than 70,000 tax professionals know and trust. With Drake SmartExtract™ (beta), a reimagined Drake Portals® experience and an AI Assistant built into Drake Tax® and Drake Tax Online®, preparers can reduce repetitive work and focus more of their time on their clients.
7 of 20 Berberine Supplements on Amazon Failed Independent Lab Testing, One Contained No Detectable Berberine
Seven of 20 berberine supplements contained far less berberine than their labels state, according to independent testing commissioned by Cata-Kor, a U.S. longevity-focused nutraceutical company. One product had no detectable berberine at all, and four delivered 5% of the stated dose or less.
Motorsport Excellence: Discover Premier Mercedes-AMG® Vehicles for Sale in Scottsdale
Driving enthusiasts seeking hand-built performance and executive luxury can now explore an exceptional selection of dynamic vehicles online. Mercedes-Benz of Scottsdale highlights an extensive lineup of Mercedes-AMG® vehicles for sale in Scottsdale. Positioned conveniently near Phoenix, AZ, the dealership provides prospective buyers with detailed performance breakdowns, transparent acquisition options, and direct inventory filters. Consequently, acquiring track-inspired performance alongside handcrafted refinement remains remarkably straightforward.
Anavex Deadline: AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
YRD Investors Have Opportunity to Lead Yiren Digital Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
YRD Investors Have Opportunity to Lead Yiren Digital Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Tamarack Resort Named Among the West's Top 25 Ski Resorts in SKI Magazine's 2027 Resort Guide
Tamarack Resort has been named the No. 25 ski resort in the West in SKI Magazine's 2027 Resort Guide, marking the Idaho destination's debut in the publication's annual rankings of North America's leading ski resorts.
Source: PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.